Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK.

Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, Harchowal J, Raftery J, Rajkumar C; PRIME study group.

Br J Clin Pharmacol. 2018 May 22. doi: 10.1111/bcp.13613. [Epub ahead of print]

PMID:
29790202
2.

Development and Relationships Between Phonological Awareness, Morphological Awareness and Word Reading in Spoken and Standard Arabic.

Schiff R, Saiegh-Haddad E.

Front Psychol. 2018 Apr 9;9:356. doi: 10.3389/fpsyg.2018.00356. eCollection 2018.

3.

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 May;17(5):921-930. doi: 10.1158/1535-7163.MCT-17-0302. Epub 2018 Mar 28.

PMID:
29592880
4.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

PMID:
29578538
5.

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.

Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV.

Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.

PMID:
29574636
6.

Community managed alcohol programs in Canada: Overview of key dimensions and implementation.

Pauly BB, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, Gray E, Krysowaty B, Ivsins A, Schiff R, Stockwell T.

Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S132-S139. doi: 10.1111/dar.12681. Epub 2018 Mar 24.

PMID:
29573059
7.

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.

Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.

Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2.

PMID:
29437766
8.

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.

9.

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.

Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R, Irie HY.

NPJ Breast Cancer. 2017 Nov 17;3:45. doi: 10.1038/s41523-017-0047-1. eCollection 2017.

10.

Introduction to Special Issue: Spelling and Morphology in Different Orthographies among Readers with and without Dyslexia.

Schiff R, Joshi RM.

Dyslexia. 2017 Nov;23(4):319-323. doi: 10.1002/dys.1573. No abstract available.

PMID:
29154450
11.

The role of feedback in implicit and explicit artificial grammar learning: a comparison between dyslexic and non-dyslexic adults.

Schiff R, Sasson A, Star G, Kahta S.

Ann Dyslexia. 2017 Oct;67(3):333-355. doi: 10.1007/s11881-017-0147-5. Epub 2017 Nov 13.

PMID:
29134484
12.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

PMID:
29110152
13.

A multi-centre randomised trial to compare the effectiveness of geriatrician-led admission avoidance hospital at home versus inpatient admission.

Shepperd S, Cradduck-Bamford A, Butler C, Ellis G, Godfrey M, Gray A, Hemsley A, Khanna P, Langhorne P, McCaffrey P, Mirza L, Pushpangadan M, Ramsay S, Schiff R, Stott D, Young J, Yu LM.

Trials. 2017 Oct 23;18(1):491. doi: 10.1186/s13063-017-2214-y.

14.

Development of quality metrics for ambulatory care in pediatric patients with tetralogy of Fallot.

Villafane J, Edwards TC, Diab KA, Satou GM, Saarel E, Lai WW, Serwer GA, Karpawich PP, Cross R, Schiff R, Chowdhury D, Hougen TJ.

Congenit Heart Dis. 2017 Dec;12(6):762-767. doi: 10.1111/chd.12523. Epub 2017 Sep 7. Review.

PMID:
28880457
15.

Infective endocarditis in adults with congenital heart disease remains a lethal disease.

Tutarel O, Alonso-Gonzalez R, Montanaro C, Schiff R, Uribarri A, Kempny A, Grübler MR, Uebing A, Swan L, Diller GP, Dimopoulos K, Gatzoulis MA.

Heart. 2018 Jan;104(2):161-165. doi: 10.1136/heartjnl-2017-311650. Epub 2017 Jul 28.

PMID:
28754810
16.

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.

Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R.

Breast. 2017 Aug;34 Suppl 1:S19-S26. doi: 10.1016/j.breast.2017.06.022. Epub 2017 Jul 4. Review.

PMID:
28687441
17.

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15.

18.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

PMID:
28487443
19.

Effect of chunk strength on the performance of children with developmental dyslexia on artificial grammar learning task may be related to complexity.

Schiff R, Katan P, Sasson A, Kahta S.

Ann Dyslexia. 2017 Jul;67(2):180-199. doi: 10.1007/s11881-017-0141-y. Epub 2017 Apr 13.

PMID:
28409401
20.

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Jeselsohn R, De Angelis C, Brown M, Schiff R.

Curr Oncol Rep. 2017 May;19(5):35. doi: 10.1007/s11912-017-0591-8. Review.

PMID:
28374222
21.

Spelling and Morphology in Dyslexia: A Developmental Study Across the School Years.

Schiff R, Levie R.

Dyslexia. 2017 Nov;23(4):324-344. doi: 10.1002/dys.1549. Epub 2017 Jan 25.

PMID:
28124462
22.

Online and offline inferential and textual processing of poor comprehenders: Evidence from a probing method.

Yeari M, Elentok S, Schiff R.

J Exp Child Psychol. 2017 Mar;155:12-31. doi: 10.1016/j.jecp.2016.10.011. Epub 2016 Nov 25.

PMID:
27894004
23.

Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.

Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS, Li K.

Oncogene. 2017 May 18;36(20):2910-2918. doi: 10.1038/onc.2016.433. Epub 2016 Nov 28.

24.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K.

Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.

25.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

26.

Performance of children with developmental dyslexia on high and low topological entropy artificial grammar learning task.

Katan P, Kahta S, Sasson A, Schiff R.

Ann Dyslexia. 2017 Jul;67(2):163-179. doi: 10.1007/s11881-016-0135-1. Epub 2016 Oct 19.

PMID:
27761876
27.

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.

Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS.

Nat Commun. 2016 Oct 3;7:12991. doi: 10.1038/ncomms12991.

28.

Online inferential and textual processing by adolescents with attention-deficit/hyperactivity disorder during reading comprehension: Evidence from a probing method.

Yeari M, Avramovich A, Schiff R.

J Clin Exp Neuropsychol. 2017 Jun;39(5):485-501. doi: 10.1080/13803395.2016.1236906. Epub 2016 Sep 29.

PMID:
27681540
29.

Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.

Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS.

Mol Cancer Res. 2016 Oct;14(10):920-927. Epub 2016 Aug 3.

30.

Do dyslexic individuals present a reduced visual attention span? Evidence from visual recognition tasks of non-verbal multi-character arrays.

Yeari M, Isser M, Schiff R.

Ann Dyslexia. 2017 Jul;67(2):128-146. doi: 10.1007/s11881-016-0132-4. Epub 2016 Jun 21.

PMID:
27329474
31.

Eye Movement Performance on the Stroop Test in Adults With ADHD.

Vakil E, Mass M, Schiff R.

J Atten Disord. 2016 Apr 8. pii: 1087054716642904. [Epub ahead of print]

PMID:
27060499
32.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

33.

Implicit learning deficits among adults with developmental dyslexia.

Kahta S, Schiff R.

Ann Dyslexia. 2016 Jul;66(2):235-50. doi: 10.1007/s11881-016-0121-7. Epub 2016 Feb 10.

PMID:
26864577
34.

Protocol for a Prospective (P) study to develop a model to stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK (The PRIME study).

Stevenson J, Parekh N, Ali K, Timeyin J, Bremner S, Van Der Cammen T, Allen J, Schiff R, Harchowal J, Davies G, Rajkumar C.

BMC Geriatr. 2016 Jan 19;16:22. doi: 10.1186/s12877-016-0191-8.

35.

Word and line bisection in typical and impaired readers and a cross-language comparison.

Gabay Y, Gabay S, Henik A, Schiff R, Behrmann M.

Brain Lang. 2015 Nov;150:143-52. doi: 10.1016/j.bandl.2015.09.005. Epub 2015 Nov 3.

PMID:
26457923
36.

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Nov;17(6):1523-4. doi: 10.1208/s12248-015-9822-9. No abstract available.

37.

The changing role of ER in endocrine resistance.

Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R.

Breast. 2015 Nov;24 Suppl 2:S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10. Review.

38.

Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X.

Clin Breast Cancer. 2015 Dec;15(6):448-457.e2. doi: 10.1016/j.clbc.2015.06.001. Epub 2015 Jun 19.

39.

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R.

Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30. Review.

40.

Metacognitive Strategies.

Schiff R, Nuri Ben-Shushan Y, Ben-Artzi E.

J Learn Disabil. 2017 Mar/Apr;50(2):143-157. doi: 10.1177/0022219415589847. Epub 2016 Aug 4.

PMID:
26054726
41.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

42.

Resistance to Anti-HER2 Therapies in Breast Cancer.

Rimawi MF, De Angelis C, Schiff R.

Am Soc Clin Oncol Educ Book. 2015:e157-64. doi: 10.14694/EdBook_AM.2015.35.e157. Review.

43.

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB.

AAPS J. 2015 Sep;17(5):1144-56. doi: 10.1208/s12248-015-9782-0. Epub 2015 May 13. Erratum in: AAPS J. 2015 Nov;17(6):1523-4.

44.

Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells.

Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang EC.

Cell Biosci. 2015 Mar 8;5:10. doi: 10.1186/s13578-015-0001-6. eCollection 2015.

45.

A pilot study of colon lymph node counts on Faxitron (radiographs) compared with pathology reports.

Chiapaikeo D, Pham DV, Schiff R, Goldfarb MA, Arvanitis ML, Dressner RM, Shinde T.

Am Surg. 2015 Mar;81(3):E90-2. No abstract available.

PMID:
25760176
46.

Probabilistic category learning in developmental dyslexia: Evidence from feedback and paired-associate weather prediction tasks.

Gabay Y, Vakil E, Schiff R, Holt LL.

Neuropsychology. 2015 Nov;29(6):844-54. doi: 10.1037/neu0000194. Epub 2015 Mar 2.

47.

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M.

Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Erratum in: Cell Cycle. 2015;14(8):1339-41.

48.

Targeting HER2 for the treatment of breast cancer.

Rimawi MF, Schiff R, Osborne CK.

Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Review.

PMID:
25587647
49.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

50.

Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts.

Sine J, Urban C, Thayer D, Charron H, Valim N, Tata DB, Schiff R, Blumenthal R, Joshi A, Puri A.

Int J Nanomedicine. 2014 Dec 19;10:125-45. doi: 10.2147/IJN.S72143. eCollection 2015.

Supplemental Content

Loading ...
Support Center